A paradoxical reaction during antituberculosis therapy for congenital tuberculosis  by Park, Ji Ae et al.
CASE REPORT
A paradoxical reaction during antituberculosis
therapy for congenital tuberculosis
Ji Ae Park, Seong Shik Park, Su Eun Park *
Department of Pediatrics, School of Medicine, Pusan National University, Busan, Korea
Received 13 May 2008; received in revised form 30 October 2008; accepted 8 November 2008
Corresponding Editor: Sheldon T. Brown
International Journal of Infectious Diseases (2009) 13, e279—e281
http://intl.elsevierhealth.com/journals/ijid
KEYWORDS
Paradoxical reaction;
Congenital tuberculosis
Summary A paradoxical tuberculosis (TB) reaction is defined as the clinical or radiological
worsening of pre-existing TB lesions or the development of new lesions during treatment. We
treated a case of such a paradoxical reaction in a 21-day-old female infant who was diagnosed
with congenital TB and was being treated with antituberculous drugs. The paradoxical reaction
improved after additional treatment with corticosteroids. Therefore, corticosteroids might be
useful to control paradoxical reactions in patients with congenital tuberculosis.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
A ‘paradoxical reaction’ (PR) is defined as the worsening of
clinical or radiological findings following the initiation of
appropriate antituberculous treatment.1—7 Once treat-
ment starts, there should be no evidence of disease relapse
or a second diagnosis. A PR has been reported in 5—35% of
patients receiving treatment for tuberculosis (TB), mostly
in immunocompromised patients (such as those with HIV
infections).2,5,8 There are no known prior reports of a PR in
patients with congenital TB. Here, we report an infant
diagnosed with congenital TB who developed a PR during
TB therapy and improved after the administration of oral
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A 21-day-old female infant presented with fever and dyspnea
for four days, and was referred from a local hospital. The
history was significant for treatment with antibiotics for five
days because of a fever without a focus four days after birth.
Although no organisms were identified at that time, the baby
was diagnosed with sepsis. On admission to our hospital, the
patient had mild subcostal retractions and tachypnea, and
chest radiography showed diffuse patchy opacities. Our
initial diagnosis was sepsis caused by pneumonia. Despite
antibiotic treatment, the tachypnea and fever persisted, and
serial chest radiography showed progression of the lung
pathology with the presence of bilateral patchy opacities.
The patient’s mother had a persistent cough for about one
month before delivery, and was diagnosed with TB and
pleurisy in a community hospital on the ninth day of her
hospital stay. We evaluated the baby for congenital TB.
Bacterial cultures of the blood, cerebrospinal fluid and urine
were negative. The analysis of the cerebrospinal fluid wasPublished by Elsevier Ltd. All rights reserved.
Figure 1 Chest CTscan showing enlargement of lymph nodes in
the subcarinal and bilateral hilar regions, and diffuse multiple
nodules in both lung fields.
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stain, the AFB cultures, and PCR for Mycobacterium tuber-
culosis were positive. The tuberculin skin test was negative.
A chest radiograph showed bilateral multiple nodular opa-
cities, and a computerized tomography (CT) of the lung
revealed enlargement of the lymph nodes in the subcarinal
and bilateral hilar regions, as well as diffuse multiple nodules
in both lung fields (Figure 1). Based on the history and clinical
findings, we diagnosed the baby with congenital TB and
treatment (rifampicin 10 mg/kg, isoniazid 10 mg/kg, pyrazi-
namide 25 mg/kg, streptomycin 20 mg/kg) was started.
Fourteen days after treatment, the clinical symptoms
improved and the patient was discharged. However, she
was readmitted to hospital two months later with a fever,
cough, wheezing and respiratory difficulties. Direct observed
therapy (DOT) is not performed in our country. The patient
was reported to be taking themedication at home daily; good
compliance was verified by the remaining drug. A follow-up
chest CT showed aggravation of the pre-existing TB lesion
(Figure 2). Gastric aspirates contained AFB on stain, the AFB
culture, and PCR for M. tuberculosis were all negative. TheFigure 2 Follow-up chest CT scan showing progression of the
pre-existing TB lesion.M. tuberculosis isolated during the first admission was sensi-
tive to all antituberculous drugs. There was no evidence of
other respiratory infections caused by respiratory viruses,
bacteria, Mycoplamsa pneumoniae or Pneumocystis jiroveci.
Therefore, treatment failure, drug resistance and secondary
infection were ruled out, and a PR during antituberculous
treatment was diagnosed. Oral prednisolone (1 mg/kg) was
added to the treatment regimen and the patient was gradu-
ally tapered off the prednisolone over six weeks. The clinical
symptoms improved and the chest radiographs showed nearly
complete resolution of the TB lesions.
Discussion
The development of a PR during the treatment of TB is
difficult to distinguish from treatment failure, drug resis-
tance or another secondary infection. A PR is defined as the
worsening of clinical or radiological findings, following the
initiation of appropriate TB treatment, in the absence of
evidence of disease relapse or another diagnosis.1—7 The
development of a PR is not uncommon; it is reported in up
to 35% of immunocompromised patients with HIV infection
and in fewer than 5% of immunocompetent patients.2,5,8 Our
case was a neonate with an immature immune system. Most
cases of PR have been described in adults, particularly in the
setting of recovering host immune function. T-cell responses
in neonates are defective. Qualitative and quantitative dif-
ferences have been observed compared with adult immune
responses.9 Cytokine-secreting T cells increase significantly
and promote humoral and cellular immune responses during
the first six months of life.10 Therefore, the relative imma-
turity of immune responses in neonates is similar to that of
adult patients recovering from deficiencies in cell-mediated
immune responses.
The pathogenesis of a PR is unclear, but probably has an
immunological basis. There are two hypotheses: the recon-
stitution of host immune responses after the initiation of
antituberculosis therapy and a hypersensitivity reaction to
the antigens released from dying tubercle bacilli.2,8,11
Patients identified with a PR generally have a negative
tuberculin skin test and decreased lymphocyte blastogenesis
at the time of diagnosis, but a positive tuberculin skin test
and increased lymphocyte blastogenesis after the initiation
of therapy.11—13 These findings might support the hypothesis
of reconstitution of the immune response. In our case, the
patient had a higher lymphocyte count within four weeks of
the start of treatment. This findingmight support the hypoth-
esis of hypersensitivity to the dying bacilli; lipoarabinoman-
nan, a protein found in the cell wall of M. tuberculosis,
induces tumor necrosis factor-a from mononuclear phago-
cytes.2,3,11,14,15 It was not necessary to change or discontinue
the TB treatment because 95% of mycobacteria isolated were
susceptible to the initial medication used for therapy.5 Treat-
ment of PRs includes systemic corticosteroid therapy and
surgical intervention.2,3,5,16 The effect of steroid treatment
is probably the immunological regulation and reduction of
intracranial tuberculoma edema. Our patient’s symptoms
improved after treatment with oral prednisolone.
In conclusion, congenital TB is rare.17 There have been no
previous reports of a PR in a patient with congenital TB during
the course of treatment. The possibility of a PR should be
considered in TB cases with clinical deterioration. In cases
Antituberculosis therapy in congenital tuberculosis e281confirmed to be a PR, corticosteroid treatment appears to be
effective therapy.
Conflict of interest: No conflict of interest to declare.
References
1. Breen RAM, Smith CJ, Bettinson H, Dart S, Bannister B, Johnson
MA, Lipman MCI. Paradoxical reactions during tuberculosis treat-
ment in patients with and without HIV co-infection. Thorax
2004;59:704—7.
2. Vidal CG, Fernandez SR, Lacasa JM, Salavert M, Vidal R, Carbal-
leira MR, Garau J. Paradoxical response to antituberculous
therapy in infliximab-treated patients with disseminated tuber-
culosis. Clin Infect Dis 2005;40:756—9.
3. Hawkey CR, Yap T, Pereira J, Moore DA, Davidson RN, Pasvol G,
et al. Characterization and management of paradoxical upgrad-
ing reactions in HIV-uninfected patients with lymph node tuber-
culosis. Clin Infect Dis 2005;40:1368—71.
4. Mert A, Ozaras R. Paradoxical reaction: can it be seen after
completion of the anti-tuberculous therapy? Scand J Infect Dis
2004;36:78—9.
5. Cheng VCC, Ho PL, Lee RA, Chan KS, Chan KK, Woo PCY, et al.
Clinical spectrum of paradoxical deterioration during antituber-
culosis therapy in non-HIV-infected patients. Eur J Clin Microbiol
Infect Dis 2002;21:803—9.
6. Markman M, Eagleton LE. Paradoxical clinical improvement and
radiographic deterioration in anergic patients treated for far
advanced tuberculosis. N Engl J Med 1981;305:167.
7. Orlovic D, Smego RA. Paradoxical tuberculosis reactions in HIV-
infected patients. Int J Tuberc Lung Dis 2001;5:370—5.
8. Narita M, Ashkin D, Hollender E, Pitchenik A. Paradoxical wor-
sening of tuberculosis following antiretroviral therapy inpatients with AIDS. Am J Respir Crit Care Med 1998;158:
157—61.
9. Marchant A, Goldman M. T cell-mediated immune responses in
human newborns: ready to learn? Clin Exp Immunol 2005;141:
10—8.
10. Buck RH, Cordle CT, Thomas DJ, Winship TR, Schaller JP, Dugle
JE. Longitudinal study of intracellular T cell cytokine produc-
tion in infants compared to adults. Clin Exp Immunol 2002;128:
490—7.
11. Chien JW, Johnson JL. Paradoxical reactions in HIV and pulmon-
ary TB. Chest 1998;114:933—6.
12. Nicolls DJ, King M, Holland D, Bala J, Rio C. Intracranial tuber-
culomas developing while on therapy for pulmonary tuberculo-
sis. Lancet Infect Dis 2005;5:795—801.
13. Cheng VC, Yam WC, Woo PC, et al. Risk factors for development
of paradoxical response during anti-tuberculosis therapy in
HIV-negative patients. Eur J Clin Microbiol Infect Dis 2003;22:
597—602.
14. Wallis RS, Amir-Tahmasseb M, Ellner JJ. Induction of interleukin
1 and tumor necrosis factor by mycobacterial proteins: the
monocyte Western blot. Proc Natl Acad Sci USA 1990;87:
3348—52.
15. Moreno C, Taverne J, Mehlert A, Bate CA, Brealey RJ, Meager
A, et al. Lipoarabinomannan from Mycobacterium tuberculo-
sis induces the production of tumor necrosis factor from
human and murine macrophages. Clin Exp Immunol 1989;
76:240—5.
16. Safdar A, Brown AE, Kraus DH, Malkin M. Paradoxical reaction
syndrome complicating aural infection due to Mycobacterium
tuberculosis during therapy. Clin Infect Dis 2000;30:625—7.
17. Crockett M, King SM, Kitai I, Jamieson F, Richardson S, Malloy P,
et al. Nosocomial transmission of congenital tuberculosis in a
neonatal intensive care unit. Clin Infect Dis 2004;39:1719—23.
